ChemGenex to Present Pivotal Data in T315I Positive CML Patients as Oral Presentation at ASCO.

Business Wire › May 14, 2009

Linked as:

Extract

ChemGenex to Present Pivotal Data in T315I Positive CML Patients as Oral Presentation at ASCO.

MELBOURNE, Australia & MENLO PARK, Calif. -- ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral pres...

See the full content of this document

ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2013, vLex. All Rights Reserved.

Language

Contents in vLex United States

Explore vLex

For Professionals

For Partners

Company

Other documents:

Rowe's Picks | grooming for civil discourse, public service | Cyril Logar v West Virginia University Board 4th Cir 2012 | Todays Forecast Around the Country and Thursdays Temperatures to 8 P.M. | Sentenza nº 2083 de Toscana Firenze May 29 2003 | Causa nº 243/2006. Resolución nº 20207, de Corte de Apelaciones de Antofagasta, de December 22, 2006 | Causa nº 595/2005. Resolución nº 3658, de Corte de Apelaciones de San Miguel, de January 23, 2007 | causa nº 1232/2004 resolución nº 19619 de corte de apelaciones de puerto montt de december 23 2004